Cipla Limited (CIPLA) — FY25 Annual Report | 19 June 2025

· NSE 🔴 High Importance Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings

Cipla Limited's annual report for FY 2024-25 details its 89th AGM scheduled for 16 July 2025 via video conferencing, with e-voting from 12-15 July 2025. Shareholders must be listed on the register as of 9 July 2025 to participate. The report covers financial performance, including revenue of ₹27,548 crores, PAT of ₹2,802 crores, and EBITDA margin of 25.9%. Key strategic initiatives include expansion in respiratory, oncology, and biosimilars, alongside sustainability goals like 64% renewable energy usage and water positivity. Governance disclosures include board appointments, risk management, and compliance with SEBI regulations.

📄 View Original Announcement (PDF)

About Cipla Limited (CIPLA)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹1,15,682.55 Cr P/E: 25.4 ROE: 14.6% ROCE: 19.4%

View full CIPLA stock details →

📡 Get AI alerts when CIPLA files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track CIPLA — Free

📊 More CIPLA filings

See all CIPLA filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when CIPLA files new disclosures

Track CIPLA filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track CIPLA — Free

Free account · 2 AI queries/day